ClinicalTrials.gg
CompletedNCT03572647Updated Nov 3, 2022

Pharmacokinetics and Pharmacodynamics Assessment of Drug Eritromax Compared to Eprex in Healthy Subjects.

A Phase 1 interventional study of Eritromax and Eprex in Renal Insufficiency, Chronic, sponsored by Azidus Brasil. Completed at 1 site in Brazil. Open to male participants aged 20 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-11-03.

Sponsored by Azidus Brasil · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
20 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing Epoetin Alfa in Renal Insufficiency, Chronic — 1 open to participants now, 1 under way, none of them phase 3. Epoetin Alfa · Renal Insufficiency, Chronic.

Enrollment
20th of 25
40 · median 157
Started
2012
with 4 others
Phase 1
2 of 25
none open now
Registered
17th of 25
by date
Lead sponsor
2 of 25
Azidus Brasil

Among the 25 studies testing Epoetin Alfa in Renal Insufficiency, Chronic, this one is the 20th largest by enrollment, is one of 5 that started in 2012, is one of 2 in phase 1, and was the 17th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

1 of the 25 studies testing Epoetin Alfa in Renal Insufficiency, Chronic is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Epoetin Alfa

Epoetin Alfa: first FDA approval 1989 (EPOGEN/PROCRIT), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 20 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing Epoetin Alfa in Renal Insufficiency, Chronic, or all of them as a file.
02

Study summary

The epoetin is a glycoprotein and endogenous hormone, which is primarily synthesized by specific epithelial cells lining the kidney peritubular capillaries, and regulates continuous formation of red blood cells. This is a pharmacokinetics and pharmacodynamics study, in which each subject will receive the investigational product in different periods, as randomisation (Teste or Comparator). The evaluation of the profile included serum dosage of medications and reticulocyte count in peripheral blood.

Read the detailed description

This a prospective randomized and crossover study for evaluation of pharmacokinetics and pharmacodynamics of two epoetins formulations. The subjects will receive in each confinement period 4000 IU one of the investigational product subcutaneously, according to randomisation, separated by a washout period of 4 weeks. The evaluation of the profile between products included serum dosage of medications and reticulocyte count in peripheral blood. Safety evaluation data will include report od all adverse events (including type, frequency, intensity, seriousness, severity and action taken related to the investigational product study).

03

Conditions studied

  • Renal Insufficiency, Chronic

Keywords

  • Erythropoeitin
  • Chronic kidney disease
  • Anaemia
04

Who can participate

Ages eligible
20 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirm the voluntary participation and agree to all the purposes of the study by signing and dating the IC in two ways;
  • Being male, aged between 20 and 55 years, clinically healthy;
  • between 18 and 25;
  • Results of examination of between 13.8 and 15.4 g / dL and hematocrit between 41% and 49%;
  • Results of VCM, HBMC, and leukocytes within the normal range:

VCM = Between 82 to 98. Among the HBMC = 26 to 34. Among the platelets = 150,000 to 400,000 units per mL. Among the WBC = 3,500 to 10,500 units per mL and without cellular atypia.

  • Serum ferritin = Male between 36 to 262 mcg / L and women between 24 to 155 mcg / L;
  • Reticulocyte count in peripheral blood ≤ 3%;
  • Serum erythropoietin less than 30 mIU / mL.

Exclusion criteria

Exclusion Criteria:

  • Participation in clinical trials in the 12 months preceding the survey;
  • Presence of iron deficiency anemia;
  • Presence of pulmonary diseases, cardiovascular, neurological, endocrine, gastrointestinal, genitourinary or other systems;
  • Acute disease in the period of 07 days prior to inclusion;
  • Chronic administration of medication to determine, such as high blood pressure;
  • Hormone therapy in the period of 02 months prior to inclusion;
  • Administration of any drug in the 02 weeks prior to inclusion;
  • A history of anemia or hereditary;
  • research subjects with a history of chronic bleeding;
  • research subjects with a history of acute bleeding in the last 30 days;
  • History of sensitivity to biological products derived from mammals, albumin, or any component of the formulation;
  • History of or current use at least 12 months of tobacco;
  • Current or previous history (less than 12 months) of illicit drug use;
  • previous therapy with erythropoietin;
  • albumin below 3.5 g / dl or greater than 4.8 g / dL;
  • Signs or clinical history of bone marrow aplasia;
  • History of liver disease and clinical or laboratory;
  • History of renal disease and clinical or laboratory.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Test ERITROMAX

    Blausiegel Industria e Comercio Ltda. Recombinant Human Erythropoietin (ERITROMAX)

    Drug: Eritromax

  • Active comparator
    EPREX

    Janssen-Cilag Recombinant Human Erythropoietin (EPREX)

    Drug: Eprex

Interventions

  • The subjects will receive a single dose of 4000 IU epoetin alfa in each period, according to randomisation.

    Also known as: epoetin alfa

  • DrugEprex

    The subjects will receive a single dose of 4000 IU epoetin alfa in each period, according to randomisation.

    Also known as: epoetin alfa

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic - rHuEPO concentration.

    Will evaluated through the plasma rHuEPO dosage before and after drug administration.

    Time frame: Before administration (Time 0 hour) and after time 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 11 hours, 12 hours, 13 hours, 18 hours, 24 hours, 36 hours, 48 hours, 72 hours, 96 hours and 120 hours administration.

  2. Pharmacodynamics - Absolute Reticulocyte Count.

    Will evaluated through the absolute reticulocyte count at total blood.

    Time frame: Before administration (Time 0 hour) and after Time 4 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours, 96 hours, 120 hours, 144 hours, 168 hours, 192 hours, 216 hours, 240 hours and 576 hours administration.

07

Study locations

1 site
  • LAL Clínica Pesquisa e Desenvolvimento Ltda.
    Valinhos, São Paulo 13270000, Brazil
08

References and documents

Individual participant data

Plan to share: Undecided — It is believed that after the data analysis and presentation to the National Commission on Research Ethics, all data will become public.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2012, a primary completion of Nov 2012 and a completion of May 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2011
First posted
Jun 28, 2018
Start
Nov 2012
Primary completionActual
Nov 2012
CompletionActual
May 2013
Last update
Nov 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03572647
Lead sponsor
Azidus Brasil
Collaborators
Blau Farmaceutica S.A.
Responsible party
Azidus Brasil (Principal Investigator Alexandre Frederico, Azidus Brasil) — Principal investigator
First posted
Jun 28, 2018
Start date
Nov 2012
Primary completion
Nov 2012
Completion
May 2013
Last update
Nov 3, 2022

Study contacts

Alexandre Frederico, PI
principal investigator · LAL Clinica Pesquisa e Desenvolvimento Ltda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Epoetin Alfa

Start the discussion